Cellectis gains on first human data for UCART19

Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) gained $6.27 (18%) to $41.28 on NASDAQ and EUR 3.60 to EUR 36.10 on Euronext on Thursday after U.K. researchers reported that the biotech's UCART19 produced remission in a single pediatric patient with relapsed B cell acute lymphoblastic leukemia (B-ALL).

In an abstract released ahead of December's American Society of Hematology (ASH) meeting, Great Ormond Street Hospital and University College London reported that an 11-month old patient with B-ALL received a single 4.5 x 10^6/kg dose of UCART19 in June under a compassionate use protocol. The patient had previously received an allogeneic stem cell transplant and Blincyto blinatumomab from Amgen Inc. (NASDAQ:AMGN). ...